XL765 – 5 mg

Brand:
Cayman
CAS:
1349796-36-6
Storage:
-20
UN-No:
Non-Hazardous - /

Phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (Item No. 13346) (mTOR) constitutively signal and drive cell survival and proliferation in many forms of cancer.{27495,21346} XL765 is a dual inhibitor of both PI3K and mTOR, completely blocking phosphorylation of substrates at 8-16 µM.{27544,27545} Similarly, XL765 is cytotoxic to glioblastoma multiforme (GBM) xenografts in vitro, with half maximal inhibition occurring at 3.7-7.7 µM.{27545} XL765 is orally bioavailable and passes the blood-brain barrier, reducing the growth of intracranial GBM xenografts in mice.{27545} This inhibitor is effective alone or in combination therapy with other compounds in various types of cancer.{27544,27545,27543}  

 

Out of stock

SKU: - Category:

Description

A dual inhibitor of both PI3K and mTOR, completely blocking phosphorylation of substrates at 8-16 µM; induces cell death in GBM xenografts in vitro, with half maximal inhibition occurring at 3.7-7.7 µM; orally bioavailable, reducing the growth of intracranial GBM xenografts in mice


Formal name: N-[4-[[[3-[(3,5-dimethoxyphenyl)amino]-2-quinoxalinyl]amino]sulfonyl]phenyl]-3-methoxy-4-methyl-benzamide

Synonyms:  SAR245409|Voxtalisib

Molecular weight: 599.7

CAS: 1349796-36-6

Purity: ≥95%

Formulation: A crystalline solid


Product Type|Biochemicals|Kinase Inhibitors|mTOR||Product Type|Biochemicals|Kinase Inhibitors|PI3K||Product Type|Biochemicals|Small Molecule Inhibitors|Kinases||Research Area|Cancer|Cell Signaling|PI3K/Akt/mTOR Signaling